3 Results for "

memory deficiency

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "memory deficiency" in MCE Product Catalog:

2
TAT-GluA2 3Y
TAT-GluA2 3Y
0 Images
2 Cited Publications
Cat. No.: HY-P2259
CAS No.: 1404188-93-7
Target:  

iGluR HIV Integrase Adenosine Receptor

Research Areas:  

Cardiovascular Disease Neurological Disease

TAT-GluA2 3Y is a blood-brain barrier-permeable AMPA receptor inhibitory peptide that crosses cell membranes via the HIV-1 TAT protein domain. TAT-GluA2 3Y blocks the endocytosis of AMPA receptors, including the internalization of GluA1/GluA2 subunits, by disrupting interactions with the AP2, Brag2 and Syt3-GluA2 complexes, while also inhibiting long-term depression. TAT-GluA2 3Y blocks hypoxia-mediated AMPAR internalization, alleviates A1R-induced persistent synaptic inhibition, and reduces cerebral ischemic volume, neurological deficits and spatial memory deficits. TAT-GluA2 3Y blocks the effect of NLRP3 deficiency on fear generalization, inhibits amphetamine-induced behavioral/neurochemical sensitization, weakens the unconditioned stimulus-conditioned stimulus association of morphine, and promotes the extinction of morphine CPP. TAT-GluA2 3Y can be used in studies related to fear generalization, ischemic stroke, hypoxia, drug addiction and opioid addiction .
loading...
    loading...
View All Sizes
Aleplasinin
Aleplasinin
0 Images
Cat. No.: HY-14759
CAS No.: 481629-87-2
Purity:  99.59%
Synonyms: PAZ-417
Target:  

PAI-1 Amyloid-β

Research Areas:  

Neurological Disease

Aleplastinin (PAZ-417) is an orally active, blood-brain barrier permeable, selective SERPINE1 (PAI-1) inhibitor (IC50=655 nM). Aleplastinin activates the tissue type plasminogen activator (tPA)/fibrinolysis cascade by inhibiting PAI-1, thereby promoting the degradation of amyloid-β (Aβ) oligomers and monomers. Aleplastinin can significantly reduce plasma and brain Aβ levels, improve memory impairment, and reverse cognitive impairment. Aleplastinin can be used for research on Alzheimer's disease .
loading...
    loading...
View All Sizes
GT-002
GT-002
0 Images
Cat. No.: HY-P992360

Target:  

GABA Receptor

Research Areas:  

Neurological Disease Cancer

GT-002 is a partial positive allosteric modulator targeting the α3 subtype of GABAA receptors, as well as a specific binder of tumor-associated TF-glycosylated LYPD3. GT-002 mildly enhances GABA-induced chloride currents by binding to the benzodiazepine site of GABAA receptors, thereby alleviating prefrontal hypofunction and improving cognitive, memory and social interaction abilities. GT-002 can be used in research related to schizophrenia spectrum disorders, various squamous cell carcinomas, colorectal cancer, non-small cell lung cancer, and aromatic L-amino acid decarboxylase deficiency .
loading...
    loading...
View All Sizes
Assay Types